Nura Mohamed - Academia.edu (original) (raw)

Armando Marques-Guedes related author profile picture

Stephen Yablo related author profile picture

Prof. Dr. Raffaele Pisano, MSc, HDR (Habil.) related author profile picture

Mohamed Rahmouni related author profile picture

carlotta pavese related author profile picture

Timothy Morton related author profile picture

Patrick Blessinger related author profile picture

Tribeni Prasad Banerjee related author profile picture

DAMIAN K O F I MEREKU related author profile picture

Angelamaria Cardone related author profile picture

Uploads

Papers by Nura Mohamed

Research paper thumbnail of Curcumin a Colorimetric and Fluorimetric Cyanide Probe in Aqueous System and Living Cells

Curcumin a Colorimetric and Fluorimetric Cyanide Probe in Aqueous System and Living Cells

Analytical Methods

Curcumin, (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-diene-3,5-dione, a natural product obtain... more Curcumin, (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-diene-3,5-dione, a natural product obtained from the rhizome of Curcuma longa. Curcumin has been demonstrated to be strong antioxidant, anticancer and possess other diverse biological activities. In addition, curcumin...

Research paper thumbnail of Metal Organic Framework as a Potential Drug Carrier for Pulmonary Arterial Hypertension

Metal Organic Framework as a Potential Drug Carrier for Pulmonary Arterial Hypertension

Qatar Foundation Annual Research Conference Proceedings Volume 2016 Issue 1

Research paper thumbnail of Role of prostacyclin in pulmonary hypertension

Global Cardiology Science and Practice, 2014

Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vess... more Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension.

Research paper thumbnail of Curcumin a Colorimetric and Fluorimetric Cyanide Probe in Aqueous System and Living Cells

Curcumin a Colorimetric and Fluorimetric Cyanide Probe in Aqueous System and Living Cells

Analytical Methods

Curcumin, (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-diene-3,5-dione, a natural product obtain... more Curcumin, (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-diene-3,5-dione, a natural product obtained from the rhizome of Curcuma longa. Curcumin has been demonstrated to be strong antioxidant, anticancer and possess other diverse biological activities. In addition, curcumin...

Research paper thumbnail of Metal Organic Framework as a Potential Drug Carrier for Pulmonary Arterial Hypertension

Metal Organic Framework as a Potential Drug Carrier for Pulmonary Arterial Hypertension

Qatar Foundation Annual Research Conference Proceedings Volume 2016 Issue 1

Research paper thumbnail of Role of prostacyclin in pulmonary hypertension

Global Cardiology Science and Practice, 2014

Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vess... more Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension.

Log In